This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (5)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Psoriasis  • Immunotherapy  • Alert me on articles by topic

Arch Dermatol. 2005;141:1154.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

We are writing in response to Bigby’s article¹ in this issue of the ARCHIVES. Additional data for our original study² separating facial and intertriginous psoriasis are provided herein in the Table. If you compare the active drug group with the placebo group for number of patients with only facial psoriasis whose total score was 0 for disease signs and symptoms for the target lesion at the end of the study, it is clear that tacrolimus treatment showed a statistically significant benefit: the lesions on 19 (42%) of 45 patients receiving active treatment cleared compared with those of only 1 (6%) of 17 vehicle-treated patients (P = .006). There was also a statistically significant benefit for intertriginous areas only: the lesions on 32 (48%) of 67 tacrolimus-treated patients cleared compared with those on only 5 (14%) of 37 vehicle-treated patients (P<.001).

Table appears in full text version. Table. Patients Who Scored 0* . . . [Full Text of this Article]

AUTHOR INFORMATION
Mark Lebwohl, MD; Amy Freeman, MD; M. Shane Chapman, MD; Steven Feldman, MD, PhD; Jennifer Hartle, MPH; Alice Henning, MS

RELATED ARTICLE

Pimecrolimus and Tacrolimus for the Treatment of Intertriginous and Facial Psoriasis: Are They Effective?
Michael Bigby
Arch Dermatol. 2005;141(9):1152-1153.
EXTRACT | FULL TEXT